+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Biomarkers Market by Product & Service, Type, Disease, Application - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 194 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5337420
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Biomarkers Market grew from USD 52.50 billion in 2023 to USD 59.69 billion in 2024. It is expected to continue growing at a CAGR of 14.19%, reaching USD 132.98 billion by 2030.

As a Market Research Analyst at 360iResearch focusing on biomarkers, it's crucial to understand their scope and definition. Biomarkers are measurable indicators of biological states or conditions, typically used as diagnostic or prognostic tools across numerous healthcare settings. Their necessity comes from their role in disease detection, progression monitoring, and therapeutic response predictions, underpinning personalized medicine's trajectory and ensuring cost-efficient and effective healthcare delivery. Biomarkers find applications in drug discovery and development, risk assessment, and clinical trials. They are extensively applied in oncology, cardiology, neurology, and other therapeutic areas. The end-use scope includes pharmaceutical and biotechnology companies, diagnostic laboratories, and healthcare institutions. Market insights reveal that key growth influencers include technological advancements in omics research, heightened prevalence of chronic diseases, and increasing investment in R&D activities. Moreover, regulatory agencies' increasing support for biomarker-driven drug development broadens potential avenues. By integrating cutting-edge technologies like AI and machine learning, companies can streamline biomarker validation and data analysis processes, unearthing opportunities for innovations in precision medicine and co-development strategies with diagnostic and therapeutic products. However, key challenges include the complexity of biomarker validation, high costs of development, and strict regulatory landscapes, which can impede swift market growth. Moreover, variations in regulatory requirements across regions pose challenges to market players seeking international expansion. Innovations may focus on multi-biomarker panels and point-of-care testing systems that provide rapid, accurate assessments. Companies are advised to focus on collaborations with academic institutions and healthcare providers to optimize translational research, thereby accelerating biomarker-led breakthroughs. Predictive biomarkers offer untapped potential for expanding personalized therapeutics across neuropathology and rare diseases, presenting lucrative prospects. Understanding this dynamic market's nature requires vigilant monitoring of technological advancements and regulatory shifts to strategically position new product offerings that align with evolving healthcare demands.

Understanding Market Dynamics in the Biomarkers Market

The Biomarkers Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing usage of biomarkers in early detection and diagnosis of chronic disease
    • Governments and regulatory support for biomarker research
    • Growing applications of biomarkers in personalized medicine
  • Market Restraints
    • High cost and technical issues associated with developing biomarkers
  • Market Opportunities
    • Integration of biomarkers with artificial intelligence and machine learning
    • Growing interest in developing advanced noninvasive biomarkers
  • Market Challenges
    • Ethical and legal concerns regarding the use of biomarkers

Exploring Porter’s Five Forces for the Biomarkers Market

Porter’s Five Forces framework further strengthens the insights of the Biomarkers Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Biomarkers Market

External macro-environmental factors deeply influence the performance of the Biomarkers Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Biomarkers Market

The Biomarkers Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Biomarkers Market

The Biomarkers Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Biomarkers Market

The Biomarkers Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abcam PLC, APIS Assay Technologies Limited, Augurex Life Sciences Corp, Bio-Rad Laboratories, Inc., BioAgilytix, Biocrates Life Sciences AG, Biofourmis Inc., Biognosys AG, BioStarks, Charles River Laboratories, Inc., Elo Health, Inc., F. Hoffmann-La Roche, Ltd., Merck KgaA, Nightingale Health Plc, Owkin Inc., Owlstone Medical Limited, PerkinElmer, Inc., Personalis, Inc., Proteomedix AG, QIAGEN GmbH, Siemens Healthineers AG, Sino Biological Inc., Thermo Fisher Scientific, Inc., and VivoSense, Inc.

Market Segmentation & Coverage

This research report categorizes the Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Product & Service
    • Consumables
    • Services
    • Software
  • Type
    • Efficacy Biomarkers
      • Pharmacodynamic Biomarkers
      • Predictive Biomarkers
      • Prognostic Biomarkers
      • Surrogate Biomarkers
    • Safety Biomarkers
    • Validation Biomarkers
  • Disease
    • Cancer
    • Cardiovascular Diseases
    • Immunological Diseases
    • Infectious Diseases
    • Neurological Diseases
  • Application
    • Clinical Diagnostics
    • Clinical Research
    • Drug Discovery & Development
    • Personalized Medicine
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing usage of biomarkers in early detection and diagnosis of chronic disease
5.1.1.2. Governments and regulatory support for biomarker research
5.1.1.3. Growing applications of biomarkers in personalized medicine
5.1.2. Restraints
5.1.2.1. High cost and technical issues associated with developing biomarkers
5.1.3. Opportunities
5.1.3.1. Integration of biomarkers with artificial intelligence and machine learning
5.1.3.2. Growing interest in developing advanced noninvasive biomarkers
5.1.4. Challenges
5.1.4.1. Ethical and legal concerns regarding the use of biomarkers
5.2. Market Segmentation Analysis
5.2.1. Product & Service: Growing adoption of sophisticated and user-friendly biomarker software to handle the complexity of biological data
5.2.2. Application: Growing applications of biomarkers in drug development to determine the efficacy and safety of the product
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Biomarkers Market, by Product & Service
6.1. Introduction
6.2. Consumables
6.3. Services
6.4. Software
7. Biomarkers Market, by Type
7.1. Introduction
7.2. Efficacy Biomarkers
7.2.1. Pharmacodynamic Biomarkers
7.2.2. Predictive Biomarkers
7.2.3. Prognostic Biomarkers
7.2.4. Surrogate Biomarkers
7.3. Safety Biomarkers
7.4. Validation Biomarkers
8. Biomarkers Market, by Disease
8.1. Introduction
8.2. Cancer
8.3. Cardiovascular Diseases
8.4. Immunological Diseases
8.5. Infectious Diseases
8.6. Neurological Diseases
9. Biomarkers Market, by Application
9.1. Introduction
9.2. Clinical Diagnostics
9.3. Clinical Research
9.4. Drug Discovery & Development
9.5. Personalized Medicine
10. Americas Biomarkers Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Biomarkers Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Biomarkers Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Owlstone Medical's Novel Initiatives Receive the Bill & Melinda Gates Foundation Funding
13.3.2. Pioneering Research Collaboration to Enhance Treatment for Metastatic Colorectal Cancer
13.3.3. FDA Initiates Pilot Program to Regulate Companion Diagnostic Tests for Oncology Drugs
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. BIOMARKERS MARKET RESEARCH PROCESS
FIGURE 2. BIOMARKERS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BIOMARKERS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BIOMARKERS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. BIOMARKERS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BIOMARKERS MARKET DYNAMICS
TABLE 7. GLOBAL BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOMARKERS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOMARKERS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOMARKERS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOMARKERS MARKET SIZE, BY PHARMACODYNAMIC BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOMARKERS MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOMARKERS MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOMARKERS MARKET SIZE, BY SURROGATE BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOMARKERS MARKET SIZE, BY SAFETY BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOMARKERS MARKET SIZE, BY VALIDATION BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOMARKERS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOMARKERS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOMARKERS MARKET SIZE, BY IMMUNOLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOMARKERS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOMARKERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOMARKERS MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 47. CANADA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 48. CANADA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 49. CANADA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 50. CANADA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 51. CANADA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. MEXICO BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 53. MEXICO BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 54. MEXICO BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 55. MEXICO BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 56. MEXICO BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. CHINA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 75. CHINA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. CHINA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 77. CHINA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 78. CHINA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. INDIA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 80. INDIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 81. INDIA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 82. INDIA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 83. INDIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 87. INDONESIA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 88. INDONESIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. JAPAN BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 90. JAPAN BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 91. JAPAN BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 92. JAPAN BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 93. JAPAN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 97. MALAYSIA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 98. MALAYSIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 102. PHILIPPINES BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 103. PHILIPPINES BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 107. SINGAPORE BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 108. SINGAPORE BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 112. SOUTH KOREA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 113. SOUTH KOREA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 117. TAIWAN BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 118. TAIWAN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. THAILAND BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 120. THAILAND BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 121. THAILAND BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 122. THAILAND BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 123. THAILAND BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 127. VIETNAM BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 128. VIETNAM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 135. DENMARK BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 136. DENMARK BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. DENMARK BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 138. DENMARK BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 139. DENMARK BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. EGYPT BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 141. EGYPT BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 142. EGYPT BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 143. EGYPT BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 144. EGYPT BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. FINLAND BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 146. FINLAND BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 147. FINLAND BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 148. FINLAND BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 149. FINLAND BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 150. FRANCE BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 151. FRANCE BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 152. FRANCE BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 153. FRANCE BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 154. FRANCE BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. GERMANY BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 156. GERMANY BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 157. GERMANY BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 158. GERMANY BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 159. GERMANY BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 163. ISRAEL BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 164. ISRAEL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. ITALY BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 166. ITALY BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 167. ITALY BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 168. ITALY BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 169. ITALY BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 179. NIGERIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 180. NORWAY BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 181. NORWAY BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 182. NORWAY BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 183. NORWAY BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 184. NORWAY BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. POLAND BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 186. POLAND BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 187. POLAND BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 188. POLAND BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 189. POLAND BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. QATAR BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 191. QATAR BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 192. QATAR BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 193. QATAR BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 194. QATAR BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 210. SPAIN BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 211. SPAIN BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 212. SPAIN BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 213. SPAIN BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 214. SPAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 218. SWEDEN BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 219. SWEDEN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. TURKEY BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 226. TURKEY BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 227. TURKEY BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 228. TURKEY BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 229. TURKEY BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 241. BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Biomarkers Market, which are profiled in this report, include:
  • Abbott Laboratories
  • Abcam PLC
  • APIS Assay Technologies Limited
  • Augurex Life Sciences Corp
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix
  • Biocrates Life Sciences AG
  • Biofourmis Inc.
  • Biognosys AG
  • BioStarks
  • Charles River Laboratories, Inc.
  • Elo Health, Inc.
  • F. Hoffmann-La Roche, Ltd.
  • Merck KgaA
  • Nightingale Health Plc
  • Owkin Inc.
  • Owlstone Medical Limited
  • PerkinElmer, Inc.
  • Personalis, Inc.
  • Proteomedix AG
  • QIAGEN GmbH
  • Siemens Healthineers AG
  • Sino Biological Inc.
  • Thermo Fisher Scientific, Inc.
  • VivoSense, Inc

Methodology

Loading
LOADING...

Table Information